ArticleJournal of ophthalmology2017
Systemic Associations with Residual Subretinal Fluid after Ranibizumab in Diabetic Macular Edema.
Article in Journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 34 citations in OpenAlex.
- Optical Coherence Tomography Biomarkers as Potential Predictors for Visual Function and Response to Intravitreal Therapy in Diabetic Macular Edema.Journal of vitreoretinal diseases · 2026Article
- Longitudinal renal function changes during real-world anti-vascular endothelial growth factor therapy for diabetic macular edema in Japan.Japanese journal of ophthalmology · 2025Observational
- Association between renal function and the Treatment of Diabetic Macular Edema in Long-Term Cohort Study.Scientific reports · 2024Article
- Intravitreal injection of conbercept for diabetic macular edema complicated with diabetic nephropathy.International journal of ophthalmology · 2024Article
- Prevalence and clinical implications of subretinal fluid in retinal diseases: a real-world cohort study.BMJ open ophthalmology · 2023Article
- Preliminary Study of Different Treatment Responses between Bevacizumab, Aflibercept and Dexamethasone Implant According to Renal Function in Diabetic Macular Edema Patients.Journal of clinical medicine · 2022Article
- Association of Abnormal Renal Profiles with Subretinal Fluid in Diabetic Macular Edema.Journal of ophthalmology · 2022Article
- Clinical Analysis of Persistent Subretinal Fluid after Pars Plana Vitrectomy in Macula with Diabetic Tractional Retinal Detachment.Journal of clinical medicine · 2021Article
- Statement of the German Ophthalmological Society, the German Retina Society, and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : Dated August 2019.Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021Review
- Long-term hemodialysis improved and stabilized diabetic macular edema: two case reports.International journal of ophthalmology · 2021Article
- Challenges in Diabetic Macular Edema Management: An Expert Consensus Report.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- [Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of Ophthalmologists in Germany on treatment of diabetic macular edema : Situation August 2019].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020Review
- Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema.Journal of diabetes research · 2020Article
- Article
- Association of urinary albumin excretion with central foveal thickness and intravitreal conbercept treatment frequency in patients with diabetic macular edema.International journal of ophthalmology · 2019Article
- Amelioration of diabetic nephropathy in db/db mice treated with tibetan medicine formula Siwei Jianghuang Decoction Powder extract.Scientific reports · 2018Article
- Impact of metabolic control on macular thickness in diabetic macular oedema.Diabetes & vascular disease research · 2018Article
- Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema.Therapeutic advances in ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the impact of systemic diseases on the occurrence of subretinal fluid (SRF) in diabetic macular edema (DME) and prognostic factors for residual SRF following three consecutive monthly intravitreal ranibizumab.
methodsNinety-seven eyes from 68 patients with DME who completed 3 consecutive monthly injections of ranibizumab were enrolled. Systemic parameters mainly included chronic kidney disease (CKD), hypertension, HbA1c, and insulin dependence. Renal parameters for CKD were serum creatinine, estimated glomerular filtration rate (eGFR), and serum albumin. Ocular factors were baseline central macular thickness (CMT), severity of diabetic retinopathy (DR), and status of panretinal photocoagulation (PRP).
resultsChronic kidney disease had significant correlation with baseline SRF (
conclusionsTight sugar control and poorer baseline kidney function may slow the resorption of SRF after anti-VEGF injections in patients with DME in the short term.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.